Drug Profile
Gotistobart - OncoC4
Alternative Names: BNT-316; ONC-392Latest Information Update: 19 Dec 2023
Price :
$50
*
At a glance
- Originator OncoImmune
- Developer BioNTech; OncoC4; OncoImmune
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Ovarian cancer
- Phase I/II Prostate cancer; Solid tumours
Most Recent Events
- 06 Dec 2023 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT05682443)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)